Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The experienced participants who were treated previously with (SOF/DCV) , (SOF/SMV), (SOF/RBV), or (SOF/pegINF/RBV).~* The presence of compensated liver cirrhosis was documented by ultrasonographic examination, liver biopsy, results of Fibroscan or FIB-4 score, and laboratory markers, like FIB-4 \> 3.25 (advanced fibrosis or cirrhosis), albumin \< 3.5, total bilirubin \> 1.2, and also confirmed by clinical characteristics such as lower limb edema, splenomegaly, esophageal varices.~Exclusion Criteria:~* liver disease of non-HCV GT4 etiology, coinfection with hepatitis B or HIV~* poorly controlled diabetes (HbA1C \> 8)~* participants, hepatocellular carcinoma, a history of extrahepatic malignancy in the 5 years prior to the study~* renal failure~* evidence of hepatic decompensation~* blood picture abnormalities such as anemia (hemoglobin concentration of \< 10 g/dL)~* thrombocytopenia (platelets count \< 50,000 cells/mm3).~* major severe illness such as congestive heart failure and respiratory failure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cirrhotic Participants (Type: ACTIVE_COMPARATOR): The experienced participants(113 participants) who failed prior DAA treatments. They were allocated to cirrhotic (30 participants) and treated for 12 weeks.
- Non-cirrhotic Participants (Type: ACTIVE_COMPARATOR): The experienced non-cirrhotic participants(83 participants) who failed prior DAA treatments. They were treated for 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).